Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
20 May 2024
|
|
23:07 | User:Rithish Nimmagadda 3 changes history +62 [Rithish Nimmagadda (3×)] | |||
|
|
23:07 (cur | prev) +25 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:32 (cur | prev) +23 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:18 (cur | prev) +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 23:07 | Velmanase alfa-tycv diffhist +7,709 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...") | ||||
|
|
N 20:36 | Retifanlimab-dlwr 3 changes history +8,754 [Rithish Nimmagadda (3×)] | |||
|
|
20:36 (cur | prev) −296 Rithish Nimmagadda talk contribs | ||||
|
|
20:33 (cur | prev) +86 Rithish Nimmagadda talk contribs | ||||
| N |
|
20:31 (cur | prev) +8,964 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...") | |||
| N 20:18 | Tofersen diffhist +3,936 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...") | ||||
| m 19:55 | Non-degenerate nucleotides per response element diffhist −51 Marshallsumter talk contribs (→Tabulation of counts) | ||||
|
|
03:56 | Leniolisib 2 changes history +3,116 [Alen Antony (2×)] | |||
|
|
03:56 (cur | prev) +1,712 Alen Antony talk contribs | ||||
|
|
03:38 (cur | prev) +1,404 Alen Antony talk contribs | ||||
19 May 2024
| 21:29 | Industrial and organizational psychology diffhist +282 Badgettrg talk contribs (→Engagement) | ||||
| m 08:44 | Non-degenerate nucleotides per response element diffhist −58 Marshallsumter talk contribs (→Tabulation of counts) | ||||
| 03:54 | Chronic obstructive pulmonary disease history and symptoms diffhist +1,728 Kosar Doraghi talk contribs | ||||
18 May 2024
| 16:02 | User:Rithish Nimmagadda diffhist +18 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
N 16:02 | Ritlecitinib 2 changes history +10,128 [Rithish Nimmagadda (2×)] | |||
|
|
16:02 (cur | prev) +22 Rithish Nimmagadda talk contribs | ||||
| N |
|
16:01 (cur | prev) +10,106 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...") | |||
|
|
00:29 | User:Archana.vajjala 2 changes history 0 [Archana.vajjala (2×)] | |||
|
|
00:29 (cur | prev) −6 Archana.vajjala talk contribs (→Dr Archana Yadav Vajjala) Tags: Manual revert Visual edit | ||||
|
|
00:23 (cur | prev) +6 Archana.vajjala talk contribs Tags: Manual revert Visual edit | ||||
17 May 2024
|
|
23:29 | User:Archana.vajjala 5 changes history +2 [Archana.vajjala (5×)] | |||
|
|
23:29 (cur | prev) −6 Archana.vajjala talk contribs (→Dr Archana Yadav Vajjala) Tag: Visual edit | ||||
|
|
23:29 (cur | prev) +24 Archana.vajjala talk contribs (→Work Experience) Tag: Visual edit | ||||
|
|
09:46 (cur | prev) +3 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
09:36 (cur | prev) +6 Archana.vajjala talk contribs (→Archana Vajjala) Tag: Visual edit | ||||
|
|
06:28 (cur | prev) −25 Archana.vajjala talk contribs (→Work Experience) Tag: Visual edit | ||||
|
|
20:01 | Leniolisib 4 changes history +3,011 [Alen Antony (4×)] | |||
|
|
20:01 (cur | prev) +305 Alen Antony talk contribs | ||||
|
|
19:37 (cur | prev) +3 Alen Antony talk contribs | ||||
|
|
19:36 (cur | prev) +1,179 Alen Antony talk contribs | ||||
|
|
18:56 (cur | prev) +1,524 Alen Antony talk contribs | ||||
|
|
17:21 | User:Rithish Nimmagadda 3 changes history +49 [Rithish Nimmagadda (3×)] | |||
|
|
17:21 (cur | prev) +17 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
16:58 (cur | prev) +15 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
15:40 (cur | prev) +17 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 17:21 | Quizartinib diffhist +8,825 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...") | ||||
| N 16:40 | Lotilaner diffhist +2,182 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...") | ||||
| 15:38 | Bimekizumab diffhist +7,057 Rithish Nimmagadda talk contribs | ||||
16 May 2024
| m 18:53 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Averages per Orders) | ||||
|
|
N 14:41 | Leniolisib 3 changes history +359 [Alen Antony (3×)] | |||
|
|
14:41 (cur | prev) +2 Alen Antony talk contribs | ||||
|
|
14:40 (cur | prev) −2 Alen Antony talk contribs | ||||
| N |
|
14:40 (cur | prev) +359 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}") | |||
|
|
14:34 | Trofinetide 6 changes history +5,945 [Alen Antony (6×)] | |||
|
|
14:34 (cur | prev) +1,803 Alen Antony talk contribs | ||||
|
|
14:19 (cur | prev) −1 Alen Antony talk contribs Tag: Manual revert | ||||
|
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs | ||||
|
|
N 10:15 | Avacincaptad pegol 2 changes history +3,387 [Muhammad Waleed (2×)] | |||
|
|
10:15 (cur | prev) +132 Muhammad Waleed talk contribs | ||||
| N |
|
10:11 (cur | prev) +3,255 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...") | |||
|
|
10:14 | Talquetamab-tgvs 2 changes history +2,312 [Muhammad Waleed (2×)] | |||
|
|
10:14 (cur | prev) +505 Muhammad Waleed talk contribs | ||||
|
|
09:28 (cur | prev) +1,807 Muhammad Waleed talk contribs | ||||
| 09:31 | Upload log Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey) | ||||
.png){kind=link}
|
|
07:07 | User:AED 4 changes history +102 [Alara E. Dagsali (4×)] | |||
|
|
07:07 (cur | prev) +21 Alara E. Dagsali talk contribs | ||||
|
|
06:42 (cur | prev) +24 Alara E. Dagsali talk contribs | ||||
|
|
06:33 (cur | prev) +27 Alara E. Dagsali talk contribs | ||||
|
|
06:22 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
|
|
N 07:06 | Diclofenac Patch 2 changes history +48,613 [Alara E. Dagsali (2×)] | |||
|
|
07:06 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
07:06 (cur | prev) +48,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...") | |||
|
|
N 06:42 | Cortisone Acetate 2 changes history +14,098 [Alara E. Dagsali (2×)] | |||
|
|
06:42 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:42 (cur | prev) +14,095 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...") | |||
|
|
N 06:33 | Clocortolone Pivalate 2 changes history +4,446 [Alara E. Dagsali (2×)] | |||
|
|
06:33 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:32 (cur | prev) +4,443 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...") | |||
|
|
N 06:21 | Scorpion 2 changes history +12,448 [Alara E. Dagsali (2×)] | |||
|
|
06:21 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
| N |
|
06:20 (cur | prev) +12,418 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...") | |||
15 May 2024
|
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
|
20:43 (cur | prev) +535 Badgettrg talk contribs | ||||
| 14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs | ||||
|
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") | |||
|
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
|
04:40 (cur | prev) +135 Alen Antony talk contribs | ||||
|
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
|
01:09 (cur | prev) +59 Alen Antony talk contribs | ||||
|
|
m 03:31 | Non-degenerate nucleotides per response element 2 changes history −129 [Marshallsumter (2×)] | |||
| m |
|
03:31 (cur | prev) −3 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
03:27 (cur | prev) −126 Marshallsumter talk contribs (→Tabulation of counts) | |||
14 May 2024
|
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
|
21:34 (cur | prev) +94 Alen Antony talk contribs | ||||
|
|
m 20:44 | Non-degenerate nucleotides per response element 4 changes history +356 [Marshallsumter (4×)] | |||
| m |
|
20:44 (cur | prev) +391 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
20:07 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:40 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:23 (cur | prev) −35 Marshallsumter talk contribs | |||
| 04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs | ||||
13 May 2024
| N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") | ||||